CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
about
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responsesT-Cell Therapy: Options for Infectious DiseasesMolecular characterization of virus-induced autoantibody responses.Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity.HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancerEffective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.In vivo requirement for Atg5 in antigen presentation by dendritic cells.NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.Anatomy of CD1-lipid antigen complexes.Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes.Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapyTransduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.GM-CSF-based cancer vaccines.GM-CSF-secreting melanoma vaccines.Antigen-specific immunotherapy and cancer vaccines.Design of multi-epitope, analogue-based cancer vaccines.Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvantRelative paradigms between autoantibodies in lupus and autoantibodies in cancer.Rapid generation of NY-ESO-1-specific CD4(+) THELPER1 cells for adoptive T-cell therapy.HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell linesIdentification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis.Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.NY-ESO-1 immunotherapy for multiple myeloma.Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapyGeneration of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation.Autoimmune thyroid disease elicited by NY-ESO-1 vaccination.
P2860
Q24531314-2F4EBB64-B2DD-40EC-A305-FA612021E186Q24678759-822C1196-F30F-44BC-9A80-AA5D1C291CF4Q26786661-F6FBF2D2-52A7-4B2F-9E01-8A9F25DDA623Q31110185-54A2750B-F07B-4D51-8D5C-5D4D91444375Q33530024-7B907B85-F45D-4C05-ABB1-21F19F3F614EQ33909892-232A4B91-4BB4-4D4E-9B7A-417E8829917AQ33994533-B53B8AC6-F8AD-44E7-BA74-8DA3AA1C8266Q34154427-3089AF3C-3056-4977-9403-F31A9FE786E9Q34376166-1D93A614-C310-48DC-80D6-E8710D9EC09BQ34388367-0664E5D7-F0B8-4C4E-982C-8426267AD3E2Q34415144-48142501-D2B4-42FF-B8F1-DA30180546CAQ34429991-2E177DCF-8CBF-4B33-9B40-88E3B09234D9Q34461203-0E3C85EA-D2EE-426C-94DD-80477FD7E4AEQ34593324-5ABFAF8B-37D2-41FC-9B6A-3A6D17012184Q34599387-A789F8A2-A977-4688-B175-D4639E4E4F41Q34795354-93C5D763-7AC5-4082-9F6D-66A81EB3AACCQ34959906-EE9D85ED-F2EC-4A54-869C-494653A9F6E7Q35005930-B2F57350-34EA-4B77-BA11-78C647251AB3Q35005952-A1145D7C-048C-40C7-AC08-A3F34E510465Q35146599-D568C018-AF2C-419D-AB34-DAF95B5576DEQ35199473-0B8A992F-DCF3-47F4-AB27-0CEBC26588CFQ35207535-559A3650-8233-47CA-ACC7-CC168377EED4Q35319290-AFB7513C-81C3-4B1F-A675-8EA8B8B1589BQ35583352-6EA99B64-2EDD-4A4A-A1DD-0020625A2206Q35799353-3003B99F-9FF6-4F18-BB6A-57C7C08765CDQ35996647-F398938C-D5C8-4556-9164-A7282E62F97AQ36327142-93D83F46-EEC5-4961-9181-8B888A4CDC1FQ36369709-63BD1EC7-8AF0-4AE3-AF48-7B362C4F544AQ36430745-D1788E32-6213-4D02-9E8E-95F8E878F347Q36471827-C509EA92-AAD5-49D0-BF0E-86CD4AF0CA46Q36509692-AE6F3F56-4C12-42EE-AB22-D73F27B1556EQ36637651-955C1F54-1A7C-40BF-AFDF-492033EFD45AQ36908561-2C055CF5-0AFD-4A03-85D2-2564A3D90AC4Q36924658-E47476FF-3235-49BC-BBC8-12B4A9D7BF30Q36986730-AD8B5993-189E-4580-A642-B78E243FC33AQ37139813-4B79F45F-89A8-4FB4-AA52-16CCC9F526C4Q37370515-CE429A0E-FDC1-4E9D-9F7E-42875B3F4F59Q37513115-94D45D46-8811-4697-984E-76581251D182Q37569023-08CC1045-DD17-43B8-A475-356488FC2F78Q37587971-E5E493F6-774F-4C8A-B8BD-DB26038BFF62
P2860
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
CD4(+) T cell recognition of M ...... NY-ESO-1 antibody production.
@ast
CD4(+) T cell recognition of M ...... NY-ESO-1 antibody production.
@en
type
label
CD4(+) T cell recognition of M ...... NY-ESO-1 antibody production.
@ast
CD4(+) T cell recognition of M ...... NY-ESO-1 antibody production.
@en
prefLabel
CD4(+) T cell recognition of M ...... NY-ESO-1 antibody production.
@ast
CD4(+) T cell recognition of M ...... NY-ESO-1 antibody production.
@en
P2093
P2860
P356
P1476
CD4(+) T cell recognition of M ...... NY-ESO-1 antibody production.
@en
P2093
P2860
P304
P356
10.1073/PNAS.061507398
P407
P577
2001-03-20T00:00:00Z